Page 60 - Boxed Warning News Today

U.S. Food and Drug Administration Approves Expanded Indication of Gilead’s Biktarvy® for Treatment of HIV-1 in Pediatric Populations

Nonpharmacologic in addition to pharmacologic treatments can improve the overall quality of life of patients with autoimmune and rheumatic diseases.

Full analysis of Phase 3b NOVA study provides insights on efficacy of every six-week dosing with natalizumab as compared to the approved every four-week dosingReal-world analysis shows significantly lower

/PRNewswire/ -- Vertice Pharma announces the results of a recent study demonstrating the bioequivalence of Thyquidity™, an oral liquid solution of...

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today detailed results from two pivotal Phase 3 trials (BRAVE-AA1 and...

ABBVie today announced that the U.S. Food and Drug Administration approved QULIPTA™ for the preventive treatment of episodic migraine in adults. 1 QULIPTA is the first and only oral calcitonin gene-related peptide receptor antagonist specifically developed for the preventive treatment of migraine. 2 Experience the interactive Multichannel News Release here: "Millions of people living with migraine often lose days ...

(BPT) - A fall, a broken wrist and a misdiagnosis. That’s how Julie’s story started.

WELIREG Approved for Adult Patients With VHL Disease Who Require Therapy for Associated Renal Cell Carcinoma, Central Nervous System Hemangioblastomas, or Pancreatic Neuroendocrine Tumors, Not Requiring Immediate Surgery WELIREG Expands Merck’s Oncology Portfolio as the First and Only Systemic Therapy Approved for These Patients With VHL Disease Merck known as MSD outside the United States and Canada, today ...

/PRNewswire/ -- Neurelis, Inc., announced today that it has completed a senior term loan facility of up to $150 million from OrbiMed, one of the leading...

Press release content from PR Newswire. The AP news staff was not involved in its creation. Lilly and Incyte provide update on supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis July 16, 2021 GMT INDIANAPOLIS, July 16, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) will not meet the Prescription Drug User Fee Act (PDUFA) action date for the s...